Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

B Glimelius

Showing results (381-390 of 416) with videos related to

Pageof 42
Sort By:
European Journal of Cancer (Oxford, England : 1990)|March 4, 2014
RAS mutations and cetuximab in locally advanced rectal cancer: results of the EXPERT-C trialF Sclafani, D Gonzalez, D Cunningham, et al.
European Journal of Cancer (Oxford, England : 1990)|August 26, 1998
Bolus injection (2-4 min) versus short-term (10-20 min) infusion of 5-fluorouracil in patients with advanced colorectal cancer: a prospective randomised trial. Nordic Gastrointestinal Tumour Adjuvant Therapy GroupB Glimelius, A Jakobsen, W Graf, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 11, 2009
A window of opportunity phase II study of enzastaurin in chemonaive patients with asymptomatic metastatic colorectal cancerB Glimelius, M Lahn, S Gawande, et al.
ESMO Open|October 22, 2023
Corrigendum to "Authors' reply-Does the RAPIDO trial suggest a benefit of post-operative chemotherapy after preoperative chemoradiation in rectal cancer? No, it does not": [ESMO Open 8 (2023) 101645]W H Zwart, E A Dijkstra, H Putter, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 29, 2022
Authors' reply-A sensitivity analysis of the RAPIDO clinical trialE A Dijkstra, W H Zwart, H Putter, et al.
ESMO Open|September 15, 2023
Authors' reply-Does the RAPIDO trial suggest a benefit of post-operative chemotherapy after preoperative chemoradiation in rectal cancer? No, it does notW H Zwart, E A Dijkstra, H Putter, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 3, 2019
Total circulating cell-free DNA as a prognostic biomarker in metastatic colorectal cancer before first-line oxaliplatin-based chemotherapyJ Hamfjord, T K Guren, O Dajani, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 12, 2002
Clinical determinants of survival in patients with 5-fluorouracil-based treatment for metastatic colorectal cancer: results of a multivariate analysis of 3825 patientsC H Köhne, D Cunningham, F Di Costanzo, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 25, 2016
PAN-EX: a pooled analysis of two trials of neoadjuvant chemotherapy followed by chemoradiotherapy in MRI-defined, locally advanced rectal cancerF Sclafani, G Brown, D Cunningham, et al.
The New England Journal of Medicine|September 8, 2001
Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancerE Kapiteijn, C A Marijnen, I D Nagtegaal, et al.
Pageof 42

Showing results (381-390 of 416) with videos related to

Sort By:
Pageof 42
European Journal of Cancer (Oxford, England : 1990)|March 4, 2014
RAS mutations and cetuximab in locally advanced rectal cancer: results of the EXPERT-C trialF Sclafani, D Gonzalez, D Cunningham, et al.
European Journal of Cancer (Oxford, England : 1990)|August 26, 1998
Bolus injection (2-4 min) versus short-term (10-20 min) infusion of 5-fluorouracil in patients with advanced colorectal cancer: a prospective randomised trial. Nordic Gastrointestinal Tumour Adjuvant Therapy GroupB Glimelius, A Jakobsen, W Graf, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 11, 2009
A window of opportunity phase II study of enzastaurin in chemonaive patients with asymptomatic metastatic colorectal cancerB Glimelius, M Lahn, S Gawande, et al.
ESMO Open|October 22, 2023
Corrigendum to "Authors' reply-Does the RAPIDO trial suggest a benefit of post-operative chemotherapy after preoperative chemoradiation in rectal cancer? No, it does not": [ESMO Open 8 (2023) 101645]W H Zwart, E A Dijkstra, H Putter, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 29, 2022
Authors' reply-A sensitivity analysis of the RAPIDO clinical trialE A Dijkstra, W H Zwart, H Putter, et al.
ESMO Open|September 15, 2023
Authors' reply-Does the RAPIDO trial suggest a benefit of post-operative chemotherapy after preoperative chemoradiation in rectal cancer? No, it does notW H Zwart, E A Dijkstra, H Putter, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 3, 2019
Total circulating cell-free DNA as a prognostic biomarker in metastatic colorectal cancer before first-line oxaliplatin-based chemotherapyJ Hamfjord, T K Guren, O Dajani, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 12, 2002
Clinical determinants of survival in patients with 5-fluorouracil-based treatment for metastatic colorectal cancer: results of a multivariate analysis of 3825 patientsC H Köhne, D Cunningham, F Di Costanzo, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 25, 2016
PAN-EX: a pooled analysis of two trials of neoadjuvant chemotherapy followed by chemoradiotherapy in MRI-defined, locally advanced rectal cancerF Sclafani, G Brown, D Cunningham, et al.
The New England Journal of Medicine|September 8, 2001
Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancerE Kapiteijn, C A Marijnen, I D Nagtegaal, et al.
Pageof 42